What to know about the Mounjaro injection
Mounjaro is a weekly tirzepatide-based injection used in weight management. For people in the UK considering this treatment, key topics include eligibility, the prescription process, and how clinicians decide whether it is appropriate. A review by NICE, access through the NHS, and the need for regular follow-up all play an important role in understanding how the treatment is planned.
Tirzepatide belongs to a class of medications that work on two hormone receptors simultaneously, making it distinct from earlier weight loss injections. Originally developed for type 2 diabetes management, it has since been approved in the UK specifically for chronic weight management in adults meeting certain clinical criteria. Understanding the full picture of this treatment helps set realistic expectations and supports informed conversations with healthcare providers.
How tirzepatide works
Tirzepatide is a dual agonist, meaning it activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. These are hormones naturally released in the gut after eating. By mimicking and amplifying their effects, tirzepatide helps regulate blood sugar levels, slows gastric emptying, and reduces appetite. This dual mechanism is what sets it apart from single-receptor treatments. Clinical trials have shown it can lead to meaningful reductions in body weight when combined with lifestyle changes such as a calorie-controlled diet and increased physical activity.
Education process and prescribing criteria
Before tirzepatide is prescribed, patients in the UK are typically required to go through a structured education process. This involves a clinical assessment covering body mass index (BMI), existing health conditions, medication history, and lifestyle factors. Prescribing criteria generally require a BMI of 35 or above, or 30 and above when accompanied by a weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnoea. The education process is designed to ensure that patients understand what the medication does, what is expected of them in terms of lifestyle adjustments, and what realistic outcomes look like over time.
NICE assessment and NHS access
The National Institute for Health and Care Excellence (NICE) plays a central role in determining how and when tirzepatide can be accessed through the NHS. NICE has assessed tirzepatide and provided guidance on its use within specific clinical frameworks. NHS access is currently subject to eligibility criteria, and in many cases, the medication may be initiated through specialist weight management services rather than standard GP consultations. Due to high demand and supply considerations, NHS rollout has been phased, meaning not all eligible patients may be able to access it immediately through NHS channels. Private prescriptions are also available but come at a significant out-of-pocket cost.
| Provider Type | Access Route | Estimated Monthly Cost |
|---|---|---|
| NHS (via specialist services) | Referral-based, eligibility required | Covered if eligible |
| Private clinic (e.g. Superdrug Health Clinic) | Online or in-person consultation | £150–£250 per month |
| Private clinic (e.g. Boots Online Doctor) | Online consultation | £149–£219 per month |
| Independent private prescriber | GP or specialist referral | £160–£280 per month |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
Follow-up, dose adjustment, and safety
Tirzepatide is administered as a weekly subcutaneous injection, typically starting at a low dose that is gradually increased over several weeks. This titration approach is designed to minimise side effects, which commonly include nausea, vomiting, diarrhoea, and reduced appetite, particularly in the early stages of treatment. Regular follow-up appointments are a core part of the treatment process. These check-ins allow healthcare professionals to review progress, assess tolerability, and make informed decisions about dose adjustments. Safety monitoring also looks for less common but more serious effects, including pancreatitis, gallbladder issues, and heart rate changes. It is not suitable for individuals with a personal or family history of certain thyroid conditions or multiple endocrine neoplasia syndrome.
Mounjaro is not a standalone solution. Its effectiveness is closely tied to adherence to a broader lifestyle programme. Patients who engage consistently with dietary guidance, physical activity recommendations, and scheduled medical follow-ups tend to see more sustained results. As with any prescription medication, ongoing clinical oversight is essential to ensure both safety and effectiveness throughout the treatment journey.